Anticoagulation in COVID-19: not strong for too long?
Résumé
Several randomised controlled trials are currently underway to evaluate the value of increasing the dose of prophylactic anticoagulation in critically ill COVID-19 patients, either at an intermediate or therapeutic dose, in order to decrease thrombotic complications, organ failure and possibly reduce mortality in these patients.
Domaines
Sciences du Vivant [q-bio]
Origine : Fichiers produits par l'(les) auteur(s)